NCT01287624
Completed
Phase 3
A Phase III, Multicenter, Open-Label, Randomized Study of Gemcitabine Plus Cisplatin (GP) Versus Gemcitabine Plus Paclitaxel (GT) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer
ConditionsBreast Cancer
Overview
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Fudan University
- Enrollment
- 240
- Locations
- 1
- Primary Endpoint
- PFS (Progression Free Survival)
Overview
Brief Summary
This is a prospective, multi-center, open-labeled, randomized phase III clinical trial comparing overall response rate (ORR), progression free survival (PFS), overall survival (OS) and toxicity obtained with gemcitabine cisplatin combination (GP) versus gemcitabine paclitaxel combination (GT).
Detailed Description
The previous phase II study showed that gemcitabine and cisplatin combination (GP) is an effective regimen in triple negative breast cancer (TNBC). The potential therapeutic effects of GP in advanced TNBC deserve further evaluation yet. Eligible patients are randomly assigned to receive either GP or GT regimen to verify the hypothesis.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Females with age between 18 and 70 years old
- •Histological proven unresectable recurrent or advanced breast cancer
- •Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human epithelial receptor-2 (HER2) by immunohistochemistry (IHC) test. For patients with ER negative, PR negative, Her2 two plus, a negative Her2 gene amplification should be verified with FISH test. Her2 one plus may consider FISH verification.
- •No prior chemotherapy for metastatic breast cancer. Prior use of taxanes in the adjuvant/neoadjuvant setting is acceptable if completed 6 months prior to enrollment
- •At least one measurable disease according to the response evaluation criteria in solid tumor (RECIST)
- •Performance status not more than 1
- •All patients enrolled are required to have adequate hematologic, hepatic, and renal function
- •Life expectancy greater than 12 weeks
- •No serious medical history of heart, lung, liver and kidney
- •Provision of written informed consent prior to any study specific procedures
Exclusion Criteria
- •Pregnant or lactating women (female patients of child-bearing potential must have a negative serum pregnancy test within 14 days of first day of drug dosing, or, if positive, a pregnancy ruled out by ultrasound)
- •Women of child-bearing potential, unwilling to use adequate contraceptive protection during the course of the study
- •Treatment with radiotherapy at the axial skeleton within 4 weeks before the first treatment or has not recovered from all toxicities of previously administered radiotherapy
- •Treatment with an investigational product within 4 weeks before the first treatment
- •Symptomatic central nervous system metastases, except for patients with stable and asymptomatic brain metastases who have completed a course of cranial irradiation, and have at least one measurable lesion outside the brain. Radiotherapy should be completed within 4 weeks prior to the registration
- •Other active malignancies (including other hematologic malignancies) or other malignancies within the last 5 years, except for cured nonmelanoma skin cancer or cervical intraepithelial neoplasia.
- •Patient having a history of clinically significant cardiovascular, hepatic, respiratory or renal diseases, clinically significant hematological and endocrinal abnormalities, clinically significant neurological or psychiatric conditions
- •Uncontrolled serious infection
Arms & Interventions
Gemcitabine,cisplatin
Experimental
GP (gemcitabine and cisplatin)
Intervention: Gemcitabine,cisplatin (Drug)
Gemcitabine, Paclitaxel
Active Comparator
GT (gemcitabine and paclitaxel combination)
Intervention: Gemcitabine, Paclitaxel (Drug)
Outcomes
Primary Outcomes
PFS (Progression Free Survival)
Time Frame: 6 weeks
Secondary Outcomes
- Objective Response Rate (ORR)(6 weeks)
Investigators
Xichun Hu
Dr
Fudan University
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 3
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)Relapsed Small Cell Lung CancerNCT05153239PharmaMar705
Recruiting
Phase 3
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCRelapsed Small Cell Lung CancerNCT06496048Luye Pharma Group Ltd.180
Recruiting
Phase 3
Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Head and Neck Squamous Cell Carcinoma (REDUCTION-I)Head and Neck Squamous Cell CarcinomasNCT05582265Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University537
Recruiting
Phase 3
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer SubjectsBreast CancerNCT06079983Jiangsu Alphamab Biopharmaceuticals Co., Ltd400
Active, not recruiting
Phase 3
Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After ProstatectomyProstate CancerNCT04181203UNICANCER490